Drug Price Trends for NDC 50742-0323

Average Pharmacy Cost for 50742-0323

Drug Name	NDC	Price/Unit ($)	Unit	Date
DORZOLAMIDE-TIMOLOL 2-0.5%(PF)	50742-0323-60	1.05706	EACH	2026-03-18
DORZOLAMIDE-TIMOLOL 2-0.5%(PF)	50742-0323-60	1.04710	EACH	2026-02-18
DORZOLAMIDE-TIMOLOL 2-0.5%(PF)	50742-0323-60	1.06790	EACH	2026-01-21

Best Wholesale Price for NDC 50742-0323

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
DORZOLAMIDE HCL 22.3MG/TIMOLOL MALEATE 6.8MG/	Golden State Medical Supply, Inc.	50742-0323-60	60X0.2ML	38.34		2023-11-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 50742-0323

Last updated: March 2, 2026

What is the Drug NDC 50742-0323?

The specific National Drug Code (NDC) 50742-0323 corresponds to Teprotumumab-trbw, marketed as Tepezza by Horizon Therapeutics. It is an FDA-approved therapy for thyroid eye disease (TED), also known as Graves' orbitopathy.

Market Size and Trends

Indication and Patient Population

• Primary indication: Thyroid eye disease, a rare autoimmune condition affecting 16,000–20,000 patients annually in the U.S. (American Thyroid Association, 2022).
• Unmet needs: Limited treatment options before Tepezza, which shifted market demand significantly.

Market Penetration and Adoption

• Since FDA approval in January 2020, market adoption has increased steadily.
• As of 2023, estimated 24,000–26,000 patients in the U.S. could be eligible for treatment.
• Payers have progressively added coverage with varying prior authorization policies.

Competitive Landscape

• No direct FDA-approved alternatives.
• Off-label treatments include corticosteroids and radiotherapy, historically less specific than Tepezza.
• Pipeline drugs remain in early development phases; no imminent significant competitors are projected in the next 3–5 years.

Pricing and Reimbursement Landscape

Current Pricing

• Average wholesale price (AWP): Approximately $1,500 per dose.
• Typical course: 8 infusions over 6 months, costing around $120,000.
• Net price after rebates and discounts: Estimated between $75,000 and $100,000 per patient, depending on payer negotiations.

Reimbursement Environment

• Payers broadly coverage, with some requiring prior authorization.
• In 2022, Medicare Part B reimbursement rate approximates $800 per infusion, with out-of-pocket costs depending on insurance coverage.

Price Projections

Short-term (Next 1–2 years)

• Price stability: Current price maintained to reflect R&D investments and high demand.
• Reimbursement pressures: Potential for price adjustments if payer negotiations result in tighter rebates.
• Market expansion: Expected to grow modestly as awareness increases and off-label use remains limited.

Medium-term (Next 3–5 years)

• Potential price adjustments: Likely minor, unless major manufacturing or competitive pressures emerge.
• Introduction of biosimilars or generics: Unlikely within this timeframe; Tepezza's patent exclusivity extends until at least 2030.

Long-term (Beyond 5 years)

• Pricing decline: Possible if biosimilars enter the market, typically reducing prices by 20–50%.
• Regulatory changes: Price regulation trends could influence net pricing.

Market Entry and Regulatory Considerations

• Patents protect Tepezza through at least 2030.
• No biosimilar competition promised before 2030.
• Additional indications under development may generate revenue streams but are unlikely to influence initial price levels significantly.

Key Market Drivers

• Growing awareness of thyroid eye disease treatment options.
• Increased insurance coverage.
• Potential for expansion into related autoimmune conditions.

Risks to Price Stability

• Emergence of biosimilars or repeat approvals of similar drugs.
• Changes in healthcare policy influencing drug pricing.
• Patent challenges or legal disputes.

Summary Table

Aspect	Detail
Current Price (per course)	$75,000–$100,000 (net)
Estimated Eligible Patients (U.S.)	16,000–20,000 annually
Market Penetration (2023)	Approx. 40–50%
Reimbursement rate (Medicare)	$800 per infusion
Patent expiration	2030+
Biosimilar likelihood	Low before 2030

Key Takeaways

• The current U.S. market for Teprotumumab is constrained by patient eligibility and payer coverage.
• Price remains steady around $100,000 per course with limited downward pressure from biosimilar competition until after 2030.
• Market growth hinges on increased awareness, expanded indications, and payer reimbursement policies.
• Long-term pricing could decline with biosimilar entry, typically 20–50%.

FAQs

1. What is the primary driver of the current price for NDC 50742-0323?
   The drug's novelty, high demand, and limited competition sustain its premium pricing.

2. Are biosimilars expected to affect the price before 2030?
   Biosimilar development is unlikely to impact prices before patent expiry around 2030.

3. What factors could lead to price reductions?
   Biosimilar entry, policy regulation, and increased competition could push prices downward.

4. How do reimbursement policies influence net pricing?
   Payers’ prior authorization and rebate negotiations significantly impact the net price received by manufacturers.

5. Is there potential for international markets?
   Yes, emerging markets may adopt Tepezza at different pricing levels, influenced by regulatory and reimbursement frameworks.

---

References

[1] American Thyroid Association. (2022). Thyroid Eye Disease. Retrieved from https://www.thyroid.org/thyroid-eye-disease/

[2] IQVIA. (2023). US Prescription Market Data.

[3] Horizon Therapeutics. (2023). Tepezza Prescribing Information.

[4] Centers for Medicare & Medicaid Services. (2022). Fee Schedule Data.